Developing vaccines against potential pandemic influenza viruses

John Wood(Women's and Children's Hospital), G. C. Schild(National Institute for Biological Standards and Control), D. Melzack(National Institute for Biological Standards and Control), Maria Zambon(Public Health England), K. G. Nicholson(Leicester Royal Infirmary), Diane Major(National Institute for Biological Standards and Control), James S. Robertson(Brookhaven National Laboratory), Richard H. Hinton, Robert W. Newman(National Institute for Biological Standards and Control), Una Dunleavy(National Institute for Biological Standards and Control)
International Congress Series
October 1, 2001
10.1016/s0531-5131(01)00385-5
Cited by 4

Related Papers

Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
|The Lancet|2003|1.1k
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus–induced myeloid-derived suppressor cells in mice and humans
|Journal of Clinical Investigation|2008|349
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma
|British Journal of Cancer|2000|208
Location and primary structure of a major antigenic site for poliovirus neutralization
|Nature|1983|194